AbCellera ( ABCL ) and Biogen ( BIIB ) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. "Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience," said Murray McCutcheon, Ph.D., SVP, Partnering at AbCellera. "We are excited to work with Biogen on this innovative program, which has the potential to unlock multiple new approaches to treating neurological conditions."